Even though the NICE Guideline says that patients may need more frequent injections GPs are still largely ignoring or unaware of this guidance
[1] [2] Symptoms that have been described include: Injection site reactions : redness, swelling, itching, or mild bruising at the site of subcutaneous administration consistent with class effects seen with semaglutide and tirzepatide (see eMC SmPCs for Wegovy, Ozempic, and Mounjaro for comparator data) Pruritus or urticaria : patchy or widespread skin itching or redness, which may reflect a hypersensitivity response again consistent with known class effects of GLP-1-based therapies [17] Generalised skin sensitivity : heightened sensitivity to touch, temperature, or pressure beyond the injection site
I'm on GLP-1 medication with a different provider, can I switch
With more than 30 years of clinical experience and medical leadership, Dr
What the Phase 3 doses tell us The Phase 3 maintenance doses of 4mg, 9mg, and 12mg represent a refinement of the Phase 2 protocol